SYK - Stryker Corporation

NYSE - NYSE Delayed Price. Currency in USD
169.81
+0.27 (+0.16%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous Close169.54
Open169.69
Bid0.00 x 800
Ask0.00 x 1400
Day's Range168.12 - 170.16
52 Week Range137.70 - 179.84
Volume1,471,472
Avg. Volume1,433,771
Market Cap63.46B
Beta0.48
PE Ratio (TTM)63.55
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield1.88 (1.12%)
Ex-Dividend Date2018-06-28
1y Target EstN/A
Trade prices are not sourced from all markets
  • General Dynamics Wins $69M Deal for the Stryker Land Vehicle
    Zacks11 hours ago

    General Dynamics Wins $69M Deal for the Stryker Land Vehicle

    General Dynamics' (GD) Stryker Land Vehicle's capabilities include the anti-tank guided missiles, mobile C4ISR, engineering and fire support and mobile gun system.

  • Why Stryker Corporation’s (NYSE:SYK) ROE Of 11.05% Does Not Tell The Whole Story
    Simply Wall St.12 hours ago

    Why Stryker Corporation’s (NYSE:SYK) ROE Of 11.05% Does Not Tell The Whole Story

    This analysis is intended to introduce important early concepts to people who are starting to invest and want to better understand how you can grow your money by investing inRead More...

  • Is Stryker (SYK) Outperforming Other Medical Stocks This Year?
    Zacks18 hours ago

    Is Stryker (SYK) Outperforming Other Medical Stocks This Year?

    Is Stryker Corporation (SYK) Outperforming Other Medical Stocks This Year?

  • Here's Why You Should Steer Clear of Cerner (CERN) for Now
    Zacks19 hours ago

    Here's Why You Should Steer Clear of Cerner (CERN) for Now

    Cerner's (CERN) downbeat view for 2018 and soft segmental performances fail to cheer investors.

  • Masimo's (MASI) US Launch of TIR-1 to Aid Patient Monitoring
    Zacks19 hours ago

    Masimo's (MASI) US Launch of TIR-1 to Aid Patient Monitoring

    Masimo (MASI) along with Thermomedics launches TIR-1 in the United States, market prospects look solid.

  • The Zacks Analyst Blog Highlights: Schlumberger, Walgreens Boots, BNY Mellon, Stryker and Duke Energy
    Zacks20 hours ago

    The Zacks Analyst Blog Highlights: Schlumberger, Walgreens Boots, BNY Mellon, Stryker and Duke Energy

    The Zacks Analyst Blog Highlights: Schlumberger, Walgreens Boots, BNY Mellon, Stryker and Duke Energy

  • Top Analyst Reports for Schlumberger, Walgreens Boots & BNY Mellon
    Zacks2 days ago

    Top Analyst Reports for Schlumberger, Walgreens Boots & BNY Mellon

    Top Analyst Reports for Schlumberger, Walgreens Boots & BNY Mellon

  • ResMed Inks Deal With athenaHealth on Brightree's eReferral
    Zacks4 days ago

    ResMed Inks Deal With athenaHealth on Brightree's eReferral

    ResMed's (RMD) wholly owned unit Brightree remains integral to the company's group for two full years with a consistent stretch of success.

  • How Did Stryker’s Key Product Lines Do in the First Quarter?
    Market Realist4 days ago

    How Did Stryker’s Key Product Lines Do in the First Quarter?

    Stryker’s (SYK) orthopedics products mainly include implants used in hip and knee joint replacements and trauma and extremities surgeries. Total orthopedics revenues increased from $1.1 billion in Q1 2017 to $1.2 billion in Q1 2018. Revenues from knee products increased from $391 million in Q1 2017 to $419 million in Q1 2018. Revenues from hip products increased from $320 million in Q1 2017 to $331 million in Q1 2018. Trauma and extremities products generated $389 million in Q1 2018 as compared with $352 million in Q1 2017. ...

  • Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical
    Zacks4 days ago

    Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical

    Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical

  • How Much Upside Do Analysts See for Stryker?
    Market Realist7 days ago

    How Much Upside Do Analysts See for Stryker?

    In this series, we’ll analyze what analysts think about the company, how its product lines have performed, and how its first-quarter financials look. Of the 27 analysts covering Stryker in June, 18 analysts have given the stock a “buy” or higher rating, while nine analysts have given it a “hold” rating. The mean rating for the stock is 2.0 with a target price of $181.36, implying upside potential of 7.5% over the stock’s closing price of $168.75 on June 14.

  • Understanding Stryker’s Cash Flows and Valuations
    Market Realist7 days ago

    Understanding Stryker’s Cash Flows and Valuations

    In Q1 2018, Stryker (SYK) generated $297 million from operating activities as compared with $151 million in Q1 2017. This increase was primarily due to lower recall-related payments and increases in income taxes payable and working capital. Stryker used $849 million on investing activities in Q1 2018 as compared with $146 million in Q1 2017. This increase was due to Stryker’s $697 million acquisition of Entellus in Q1 2018.

  • A Look at Stryker’s Financial Performance
    Market Realist7 days ago

    A Look at Stryker’s Financial Performance

    Stryker (SYK) generated revenues of $3.2 billion in the first quarter of 2018 compared with $3.0 billion in the first quarter of 2017. The research and development expenses that Stryker incurred rose by $12 million from $192 million in the first quarter of 2017 to $204 million in the first quarter of 2018. On account of the increase in SG&A expenses, the total operating expenses incurred by Stryker rose from $1.4 billion in the first quarter of 2017 to ~$1.6 billion in the first quarter of 2018.

  • Here's Why You Should Steer Clear of Express Scripts for Now
    Zacks7 days ago

    Here's Why You Should Steer Clear of Express Scripts for Now

    Express Scripts' (ESRX) loss of major customers, downbeat 2018 earnings guidance and selling of shares to Cigna make it lower its credibility as an investment pick.

  • Is Stryker Corporation’s (NYSE:SYK) Balance Sheet A Threat To Its Future?
    Simply Wall St.8 days ago

    Is Stryker Corporation’s (NYSE:SYK) Balance Sheet A Threat To Its Future?

    There are a number of reasons that attract investors towards large-cap companies such as Stryker Corporation (NYSE:SYK), with a market cap of US$60.74B. Doing business globally, large caps tend toRead More...

  • PetMed (PETS) Optimistic About New Orders Amid Cost Woes
    Zacks8 days ago

    PetMed (PETS) Optimistic About New Orders Amid Cost Woes

    The whole of fiscal 2018 demonstrates an upbeat momentum for PetMed's (PETS) new order sales, primarily backed by aggressive advertising.

  • SYK or SRDX: Which is a Better Medical Product Stock?
    Zacks8 days ago

    SYK or SRDX: Which is a Better Medical Product Stock?

    Stryker (SYK) and Surmodics' (SRDX) strong fundamentals and rising share price make them close contenders.

  • The Wall Street Journal8 days ago

    [$$] Stryker Says It’s Not in Deal Talks With Boston Scientific

    Medical-technology company Stryker Corp. said Wednesday it is not in discussions with Boston Scientific Corp. regarding a potential takeover. On Monday, The Wall Street Journal reported Stryker had made a takeover approach to Boston Scientific, a move that would create a medical-device giant and would be the latest effort to consolidate a corner of the health-care industry that has produced a raft of large deals lately. Stryker said in a filing with the Securities and Exchange Commission on Wednesday it doesn’t typically comment on these matters, but it chose to respond following market speculation about a possible deal for Boston Scientific.

  • TheStreet.com8 days ago

    Stocks Tank Into Close, End Down More Than 100 Points After Fed Rate Hike

    CEO Blake Moret tells TheStreet he is bullish on U.S. manufacturing. Private equity is having trouble putting money to work, one veteran deal-maker tells TheStreet's sister publication The Deal. Bitcoin prices continue to be under pressure, reports TheStreet's Kinsey Grant.

  • Market Realist8 days ago

    Stryker Declines Buyout Talks with Boston Scientific

    On June 13, Stryker (SYK) said in a regulatory filing that it’s not in discussions with Boston Scientific (BSX) related to its acquisition. The company released the statement following rumors of a potential acquisition offer made by Stryker to Boston Scientific on June 11, as we reported in Boston Scientific Surges on Rumors of Takeover Bid from Stryker.

  • Stryker Says It's Not Planning To Acquire Boston Scientific
    Investor's Business Daily8 days ago

    Stryker Says It's Not Planning To Acquire Boston Scientific

    Medtech player Stryker isn't in discussions to acquire Boston Scientific, Stryker said Wednesday — prodding shares to pop as Boston Scientific stock toppled more than 6%.

  • Reuters9 days ago

    US STOCKS-Wall St flat as Fed decision awaited

    U.S. stocks were little changed on Wednesday, ahead of a widely expected interest rate hike by the Federal Reserve, with focus on its guidance on the economy and monetary policy. With the 25 basis point rate hike almost certain, market participants will parse the central bank's statement for clues on whether it will raise rates three or four times in 2018.

  • Reuters9 days ago

    US STOCKS-Wall St flat, media stocks jump after AT&T ruling

    U.S. stocks were flat on Wednesday ahead of the Federal Reserve's policy announcement, while media shares got a boost from a court approval for AT&T's $85 billion takeover of Time Warner. AT&T dropped 3.8 percent and weighed the most on the S&P telecoms index, which fell 2.6 percent. Twenty-First Century Fox surged 7.8 percent as Comcast Corp is expected to outbid Disney for some of its assets.

  • Reuters9 days ago

    Medical device maker Stryker says not in talks to buy Boston Scientific

    Stryker's shares rose 7 percent to $174 in premarket trading after falling 9 percent in the last two days. Boston Scientific's shares fell 6.8 percent to $31.60. A potential deal between Stryker and Boston Scientific would create a combined company with a market value of more than $110 billion.

  • Reuters9 days ago

    Medical device maker Stryker says not in talks to buy Boston Scientific

    Medical device maker Stryker Corp is not in talks to buy rival Boston Scientific Corp , the company said in a regulatory filing https://bit.ly/2Jy6VQB on Wednesday, two days after a media report of a potential deal between the two surfaced. Stryker's shares rose 7 percent to $174 in premarket trading after falling 9 percent in the last two days. Boston Scientific's shares fell 6.8 percent to $31.60.